Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases

Renal medullary carcinoma (RMC) was first described over two decades ago as the seventh sickle nephropathy. Survival after diagnosis with metastatic disease still rarely extends beyond 1 year, with recent reports of median overall survival in patients treated with platinum therapy being just 10 months. We describe our experience using platinum‐based chemotherapy plus the proteasome inhibitor bortezomib to treat metastatic RMC in two pediatric patients who had complete responses. One patient passed away 7 years after diagnosis, while another remains disease free nearly 2 years from diagnosis.

[1]  S. Batra.  Is There a Role for Antiangiogenic Therapy in Renal Medullary Carcinoma? , 2016, Pediatric blood & cancer.

[2]  O. Alvarez,et al.  Renal medullary carcinoma and sickle cell trait: A systematic review , 2015, Pediatric blood & cancer.

[3]  A. Palazzo,et al.  Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[4]  M. Matrana,et al.  Renal medullary carcinoma: a case report and brief review of the literature. , 2014, The Ochsner journal.

[5]  E. Vichinsky,et al.  Renal medullary carcinoma in an adolescent with sickle cell anemia , 2014, Pediatric blood & cancer.

[6]  L. Hilliard,et al.  Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma , 2010, Pediatric blood & cancer.

[7]  D. Kuhn,et al.  Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade , 2008, Clinical Cancer Research.

[8]  M. Tretiakova,et al.  Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior , 2008, Modern Pathology.

[9]  A. Billis,et al.  Renal medullary carcinoma: report of seven cases from Brazil , 2007, Modern Pathology.

[10]  G. Peters,et al.  A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.

[11]  Antonio Lopez-Beltran,et al.  2004 WHO classification of the renal tumors of the adults. , 2006, European urology.

[12]  R. Motzer,et al.  Medullary renal cell carcinoma and response to therapy with bortezomib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  B. Delahunt,et al.  History of the development of the classification of renal cell neoplasia. , 2005, Clinics in laboratory medicine.

[14]  R. Arceci,et al.  Significant responses to platinum‐based chemotherapy in renal medullary carcinoma , 2005, Pediatric blood & cancer.

[15]  K. Neville,et al.  Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  L. Schwartz,et al.  Phase II trial of bortezomib for patients with advanced renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Ximing J. Yang,et al.  Gene expression profiling of renal medullary carcinoma , 2004, Cancer.

[18]  E. Perlman,et al.  Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. , 2002, Urology.

[19]  I. Thompson,et al.  Renal medullary carcinoma: can early diagnosis lead to long-term survival? , 2000, The Journal of urology.

[20]  F. Mostofi,et al.  Renal Medullary Carcinoma The Seventh Sickle Cell Nephropathy , 1995, The American journal of surgical pathology.